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Transplant outcomes of patients receiving unrelated marrow grafts from CCR5 wild-type (1/1), CCR5D32 heterozygous (1/-) or
CCR5D32 homozygous (-/-) donors.
1/1 (n5 344) 1/- (n5 39) -/- (n5 8)
Grades II-IV 309 (90%) OR5 1 34 (87%) OR5 0.77 (0.28-2.10, P5.61) 6 (75%) OR5 0.34 (0.07-1.75, P5.20)
Grades III-IV 124 (36%) OR5 1 13 (33%) OR5 0.89 (0.44-1.79, P5.74) 1 (13%) OR5 0.25 (0.03-2.08, P5.20)
Skin 288 (84%) OR5 1 18 (46%) OR5 0.89 (0.37-2.11, P5.79) 4 (50%) OR5 0.19 (0.05-0.80, P5.02)
Liver 159 (46%) OR5 1 32 (82%) OR5 0.65 (0.33-1.30, P5.22) 2 (25%) OR5 0.39 (0.08-1.95, P5.25)
Gut 219 (64%) OR5 1 14 (36%) OR5 0.82 (0.42-1.61, P5.57) 5 (63%) OR5 0.95 (0.22-4.05, P5.95)
Chronic 207 (60%) HR5 1 19 (49%) HR5 0.96 (0.60-1.53, P5.85) 3 (38%) HR5 0.45 (0.14-1.41, P5.17)
Poster Session II S301Patients who received bone marrow from CCR5d32 homozygous
donors had lower risk of skin GVHD than the control group and the
difference is statistically significant. We screened our GVHD tissue
repository of allograft recipients, to select ten samples from skin and
lip that showed histological features of GVHD and had the most
abundant number of lymphocytes. We found that lymphocyte infil-
trates in all the samples were predominantly CCR5+ T cells. Approx-
imately 80% of CD4+ T cells in the skin and lip biopsies were
CCR5+ cells, whereas 70% of CD8+ T cells were CCR5+. Thus,
CCR5 expression was present on most CD4+ and CD8+ T cells in-
volved in the pathogenesis of skin GVHD. Using allogeneic DCs
mixed with responder PBMCs, we found CCR5 was upregulated
on the subpopulation of T cells that were actively dividing and had
acquired characteristics of activated T cells after allogeneic stimula-
tion. The majority of CCR5+ T cells were CD45RA-/CD45RO+
with decreased expression of CD62L and CD69. In addition, we
found that activated CD4+ T cells that produced cytokine TNFa,
IL-2 or IFN-g, were positive for CCR5. In addition, the TNFa
and IL-2 producing CD8+ T cells also expressed CCR5. This obser-
vation supported the notion that CCR5 is a marker for effector T
cells that actively participate in the ‘‘cytokine storm’’ of GVHD.
Our data demonstrated that CCR5+ T cells are important in mediat-
ing GVHD in human.389
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TNF-Related Apoptosis Inducing Ligand (TRAIL) is a type II
membrane protein, which can transduce apoptotic signals
through death receptor (DR) 4 and 5 molecules (only DR5 in
mice) expressed on target cells. Previous studies with TRAIL-
deficient donor T cells indicated that TRAIL is dispensable in
the development of lethal graft-versus-host disease (GVHD),
although it plays a role in thymic GVHD. In contrast,
TRAIL-deficient T cells displayed a significant loss in graft-ver-
sus-tumor (GVT) activity. In this study, we evaluated the effect
of TRAIL over-expression in donor T cells (mature and precur-
sor stage) on GVHD and GVT. Mature T cells derived from
donor splenocytes were transduced with a lentiviral TRAIL
expression vector. The transduced TRAIL+ cells were adoptively
transferred on day 0 into recipients of a T cell depleted alloge-
neic hematopoietic stem cell transplantation (TCD-AHSCT) to
assess their effects on GVHD and GVT. T cell precursors were
generated from murine hematopoietic stem cells, transduced
with lentiviral vectors and expanded using the OP9-DL1 co-cul-
ture system. Mature splenic TRAIL+ T cells were able to mount
significantly enhanced antitumor immunity compared to T cells
transduced with a control vector against tumor cell lines in vitro
and upon transfer into tumor bearing AHSCT recipients. To
our surprise, AHSCT recipients treated with TRAIL+ T cellshad significantly less GVHD. We observed increased DR5 ex-
pression on host antigen presenting cells (APC) soon after the
total body irradiation used in our preparative regimens, suggest-
ing that TRAIL+ donor T cells could eliminate host APC, re-
sulting in less GVHD. Finally, adoptive transfer of TRAIL+
precursor T cells could reconstitute the T cell compartment
and resulted in enhanced GVT activity without exacerbation
of GVHD. In conclusion, our data indicate that adoptive trans-
fer of TRAIL+ donor T cells or T cell precursors can enhance
GVT activity, while ameliorating GVHD possibly through the
elimination of host APC.390
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We present long term results in 68 children with ALL who
received highly T and B cell depleted stem cells from matched unre-
lated (n5 17) or full haplotype mismatched related donors (n5 51)
at our institution. Our aimwas tominimizeGvHDand to avoid EBV
LPD in both matched and mismatched transplantations. Remission
status was: CR1,n5 18; CR2,n5 23; $CR3,n5 12; non remission
or second transplant, n5 15. Graft manipulation was carried out
with microbeads and the CliniMACS device (indirect depletion
of T and B cells with CD34+ positive selection (n5 50); or direct
depletion with anti-CD3/anti-CD19 coated microbeads (n5 18)).
T andB cell counts were reduced for 4-5 log withmedian numbers
of residual T cells of 15 000/kg bw (CD34+ selection) and 49 000/kg
bw (CD3/19 depletion). No pharmacological immune suppression
was given after positive selection, whereas patients with CD3/19 de-
pletion received MMF. The conditioning regimens were either TBI
or Bu based (n5 50) or a toxicity reduced protocol (Flud, TT, Mel)
was used (n5 18). Rejection prophylaxis was carried out with ATG
orOKT3. Primary engraftment occurred in 85%. After recondition-
ing, final engraftment was achieved in 98%. GvHD grade 0-1 oc-
curred in 86%. 12% had grade II, 4% had grade III. Chronic
GvHD occurred in 4 patients. No GvHD related mortality was
observed. Median follow up was 5.9 years. EFS at 1 year was
56%(CR1), 51%(CR2) and 50%($CR3); EFS at 5 years was
49%(CR1), 46%(CR2) and 27%($CR3). Median survival of
patients with active disease was 0.2 years. Relapse rates at 1 year
were 0.32(CR1), 0.47(CR2) and 0.46($CR3); relapse rates at 5 years
were 0.32(CR1), 0.47(CR2) and 0.64($CR3). TRM at 1 year was
14%, causes of death remained viral and fungal infections, no EBV
LPD occurred.
Conclusions: positive selection of progenitor cells or depletion of T
and B cells can minimize acute and chronic GVHD in both matched
unrelated and mismatched related transplantations and may prevent
GvHD related mortality. Lethal infections occurred in 14% of the
patients probably due to the delayed recovery of T cells. Despite pro-
found depletion of donor T cells, relapse rates were acceptable and
remained on a stable level after the first year in patients with com-
plete remission. Thus, absence of GvHD may not necessarily be as-
sociated with high relapse rates in childhood ALL. Apart from T
